TriSalus Q2 revenue rises 1.7% to $11.4 million; operating loss widens to $9.8 million
TriSalus Life Sciences reported second quarter 2026 revenue of $11.4 million, up 1.7% from a year earlier, while its operating loss widened to $9.8 million from $7.3 million as sales and marketing spending rose. The company maintained its full-year 2026 revenue guidance of $54 million to $57 million, which it said represents growth of 19% to 26% over 2025.
Key points
- Q2 2026 revenue was $11.4 million, up 1.7% from $11.2 million in Q2 2025; gross margin rose to 86.8% from 83.9%.
- Sales and marketing expense rose to $11.4 million from $7.2 million, driving the operating loss to $9.8 million.
- Net loss attributable to common stockholders was $9.2 million, or $0.16 per share, compared with $9.0 million, or $0.27 per share, a year earlier.
- Full-year 2026 revenue guidance of $54 million to $57 million was maintained; cash and cash equivalents were $46.3 million at June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.